- This event has passed.
VT BEST Event: What’s the Big Deal? Exploring Careers in the Biopharmaceutical Industry Through the Lens of Cross-Functional Team Deal Making
September 15, 2017 @ 9:30 am - 12:30 pm
The BEST program mini-internships are designed to expose trainees to “a day on the job” for a variety of career paths, through hands-on exercises, site visits, and/or case discussions with biomedical professionals. Join the BEST Program and MedImmune for a workshop to explore different careers in the biopharmaceutical industry, using real-world licensing deals as the basis for the discussion. During this hands-on workshop, you’ll explore how pharmaceutical companies use cross-functional teams to structure deals with universities, develop term sheets and think strategically about real-world issues that impact deal-making. You’ll also gain insights about how different functions within an organization may be driven by different objectives and yet need to work toward a common goal. Attendees will also have the opportunity to apply their academic training during interactive case study discussions while gaining a better appreciation for the importance of having a strong scientific background. The guest speakers will be Scott Alban, VP Intellectual Property, and Jarrod Borkat, Senior Director, Partnering & Strategy, from MedImmune, the biologics division of AstraZeneca.
Space is limited! Participants must register in advance. To register for the mini-internship, please click here.
September 15th, 2017; 9:30 AM – 12:30 PM, Roanoke, VA
Scott Alban (B.S., Ph.D., Virginia Tech) leads the global intellectual property team, which is accountable for developing and implementing intellectual property strategies across the business, supporting business development teams in the evaluation of new opportunities and ensuring R&D and commercial assets are appropriately protected.
Jarrod Borkat is an 18‐year veteran in the biopharmaceutical industry. He joined MedImmune in 2010, where he currently serves as Senior Director, Partnering & Strategy and is responsible for spinning out companies, based on MedImmune assets.
